SCHEMBL26984900

SCHEMBL26984900

COC(=O)c1cncc(Nc2ccc(Cl)cc2F)c1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NUDT1 P36639 5/20 0.56
▸ TGFBR1 P36897 2/20 0.48
▸ CSF1R P07333 1/20 0.45
▸ ABL1 P00519 1/20 0.42
▸ EGFR P00533 1/20 0.41
▸ ACVR1B P36896 1/20 0.40
▸ ACVRL1 P37023 1/20 0.40
▸ TLR4 O00206 1/20 0.39
▸ MAP2K1 Q02750 1/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ PKM P14618 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ FGFR1 P11362 1/20 0.39
▸ FLT1 P17948 1/20 0.39
▸ EPHB2 P29323 1/20 0.39
▸ FLT4 P35916 1/20 0.39
▸ KDR P35968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30746487 1.00 NUDT1 (0.56) NUDT1TGFBR1CSF1RABL1EGFR
SCHEMBL26985024 0.85 NUDT1 (0.53) NUDT1TGFBR1CSF1RABL1EGFR
SCHEMBL30746560 0.85 NUDT1 (0.53) NUDT1TGFBR1CSF1RABL1EGFR
SCHEMBL26985120 0.82 KDM4E (0.45) CSF1RKMT2ANPC1RAB9ARXFP1
SCHEMBL31613387 0.82 KDM4E (0.45) CSF1RKMT2ANPC1RAB9ARXFP1
SCHEMBL26984971 0.77 NUDT1 (0.47) NUDT1CSF1REGFRNPSR1KMT2A
SCHEMBL30746519 0.77 NUDT1 (0.47) NUDT1CSF1REGFRNPSR1KMT2A
SCHEMBL31613386 0.76 NUDT1 (0.47) NUDT1CSF1REGFRNPSR1KMT2A
SCHEMBL30746528 0.76 NUDT1 (0.47) NUDT1CSF1REGFRMAP2K1NPSR1
SCHEMBL26985114 0.76 NUDT1 (0.47) NUDT1CSF1REGFRNPSR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS INC (US) 2026-01-01 — — US disclosed
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. 2025-09-18 — — US disclosed
EP-4551558-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS Nested Therapeutics, Inc. (US) 2025-05-14 — — EP disclosed
WO-2024010925-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed
WO-2024010925-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS MAPK6, MAPK3, MAPK1 NUDT1 1810/4885TGFBR1 1219/4885CSF1R 3256/4885
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS BRAF, MAP3K1, MAP3K5 NUDT1 2559/4885TGFBR1 2807/4885CSF1R 1602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback